Vildagliptin

Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity[1].

Product Specifications

CAS Number

[274901-16-5]

Product Name Alternative

LAF237; NVP-LAF 237

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Dipeptidyl Peptidase; Ferroptosis

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Vildagliptin.html

Purity

99.93

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

O[C@@]1(C2)C[C@H]3C[C@H](C[C@]2(NCC(N4[C@H](C#N)CCC4)=O)C3)C1

Molecular Formula

C17H25N3O2

Molecular Weight

303.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Villhauer EB, et al. 1-[[ (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano- (S) -pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem. 2003 Jun 19;46 (13) :2774-89.|[2]Wu YJ, et al. Dipeptidyl peptidase-4 inhibitor, vildagliptin, inhibits pancreatic beta cell apoptosis in associationwith its effects suppressing endoplasmic reticulum stress in db/db mice. Metabolism. 2015 Feb;64 (2) :226-35.